Financial reports
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
15 Mar 23
10-Q
2022 Q3
Quarterly report
8 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
15 Mar 22
10-Q
2021 Q3
Quarterly report
10 Nov 21
Current reports
8-K
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
20 Mar 24
8-K
UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results
13 Nov 23
8-K
UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds
13 Nov 23
8-K
UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
27 Sep 23
8-K
Termination of a Material Definitive Agreement
6 Sep 23
8-K
UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results
8 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 23
8-K
UNITY Biotechnology, Inc. Reports First Quarter 2023 Financial Results
9 May 23
8-K/A
Departure of Directors or Certain Officers
28 Apr 23
8-K
UNITY Biotechnology Announces Positive 48-Week Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic Macular Edema
24 Apr 23
Registration and prospectus
424B3
Prospectus supplement
8 Dec 23
S-3
Shelf registration
6 Dec 23
424B5
Prospectus supplement for primary offering
17 Mar 23
S-8
Registration of securities for employees
15 Mar 23
424B5
Prospectus supplement for primary offering
25 Oct 22
S-3
Shelf registration
14 Oct 22
424B5
Prospectus supplement for primary offering
19 Aug 22
424B5
Prospectus supplement for primary offering
19 Aug 22
FWP
Free writing prospectus
17 Aug 22
424B5
Prospectus supplement for primary offering
16 Aug 22
Proxies
DEF 14A
Definitive proxy
28 Apr 23
DEF 14A
Definitive proxy
13 Sep 22
PRE 14A
Preliminary proxy
30 Aug 22
DEFA14A
Additional proxy soliciting materials
29 Apr 22
DEF 14A
Definitive proxy
29 Apr 22
PRE 14A
Preliminary proxy
12 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
DEFA14A
Additional proxy soliciting materials
24 Apr 20
DEF 14A
Definitive proxy
24 Apr 20
Other
EFFECT
Notice of effectiveness
11 Dec 23
UPLOAD
Letter from SEC
7 Dec 23
CORRESP
Correspondence with SEC
7 Dec 23
EFFECT
Notice of effectiveness
25 Oct 22
UPLOAD
Letter from SEC
20 Oct 22
CORRESP
Correspondence with SEC
20 Oct 22
EFFECT
Notice of effectiveness
6 May 22
CORRESP
Correspondence with SEC
4 May 22
UPLOAD
Letter from SEC
18 Mar 22
CT ORDER
Confidential treatment order
8 Mar 22
Ownership
4
Alexander Hieu Nguyen
27 Mar 24
SC 13G/A
Alyeska Investment Group, L.P.
14 Feb 24
4
Anirvan Ghosh
5 Feb 24
4
Anirvan Ghosh
31 Jan 24
4
Anirvan Ghosh
3 Nov 23
4
Anirvan Ghosh
31 Oct 23
4
Anirvan Ghosh
15 Sep 23
144
Notice of proposed sale of securities
15 Sep 23
4
Anirvan Ghosh
3 Aug 23
144
Notice of proposed sale of securities
3 Aug 23